Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

December 13, 2013
565566
Cancer, Cancer - Melanoma
John McCann, MD
  • D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
  • Baystate Franklin Medical Center, 164 High Street, Greenfield, MA
The purpose of this study is to compare overall survival for patients receiving ipilimumab plus bevacizumab versus ipilimumab alone.
Unresectable Stage III or Stage IV Melanoma; untreated or one previous treatment.
Active
Interventional (Clinical Trial), Randomized
2
Dawn DeMarinis
413-794-4362